Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Developing the multidisciplinary and multispecialty workforce and the systems needed to sustain high-quality care from diagnosis through long-term survivorship.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

Quality of Life in Adult Cancer Patients With Underage Children: An Integrative Review.

Journal of the advanced practitioner in oncology·2023

Same author

ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.

Oncology nursing forum·2022

Same author

Implementing the Condensed Memorial Symptom Assessment Scale on an Inpatient Oncology Unit.

Clinical journal of oncology nursing·2022

Same author

Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures.

Clinical journal of oncology nursing·2021

Same author

Implementation of Survivorship Care Plans in Patients With Glioblastoma.

Journal of the advanced practitioner in oncology·2021

Same journal

How Can Oncology Nurses Learn to See Beyond the Numbers?

Clinical journal of oncology nursing·2026

Same journal

Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey.

Clinical journal of oncology nursing·2026

Same journal

The Role of Oncology Nurses in National Breast and Cervical Cancer Screening Programs.

Clinical journal of oncology nursing·2026

Same journal

Technology-Assisted Nutrition Education Program for Patients With Cancer Undergoing Gastrectomy: A Quasi-Experimental Study.

Clinical journal of oncology nursing·2026

Same journal

The Hidden Biology of Life Experience: Using SEMOARS + GEM and Precision Health for Psychoneurologic Symptoms in Hematologic Malignancies.

Clinical journal of oncology nursing·2026

Same journal

GLP-1 Medications in Oncology Nursing Practice.

Clinical journal of oncology nursing·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 12, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Larotrectinib: A Targeted Therapy for Solid Tumors.

Gabriela Mota-George¹, Susan M Schneider¹

¹Duke University.

Clinical Journal of Oncology Nursing

|March 19, 2021

Summary

This summary is machine-generated.

Larotrectinib is an effective targeted therapy for cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Oncology nurses play a vital role in patient education for this treatment.

Keywords:

gene fusion genetic variants larotrectinib solid tumor targeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: Nov 12, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare in most cancers but prevalent in certain rare tumor types.
The U.S. Food and Drug Administration has approved larotrectinib for specific NTRK gene fusion-positive cancers.
Future cancer treatment is expected to shift towards genetic variants over tumor histology.

Purpose of the Study:

To provide an overview of larotrectinib, a targeted therapy.
To review clinical trial results of larotrectinib.
To highlight implications for oncology nurses.

Main Methods:

Review of clinical trial data for larotrectinib.
Analysis of treatment efficacy and patient outcomes.
Identification of key nursing responsibilities in patient care.

Main Results:

Larotrectinib demonstrates efficacy in treating patients with NTRK gene fusion-positive cancers.
Oncology nurses are crucial for patient education regarding larotrectinib's dosing, administration, side effects, and precautions.

Conclusions:

Larotrectinib represents a significant targeted treatment option for a specific subset of cancer patients.
Effective patient education by oncology nurses is essential for optimal outcomes and safety when using larotrectinib.